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Background: Cervical cancer is associated with high morbidity and mortality rates among young women in Japan.
The objective of this study was to assess and project the economic burden associated with cervical cancer in Japan
and identify factors affecting future changes in this burden on society.
Methods: Utilizing government-based statistical nationwide data, we used the cost of illness (COI) method to
estimate the COIs for 1996, 1999, 2002, 2005, 2008, and 2011 to make predictions for 2014, 2017, and 2020. The COI
comprised direct and indirect costs (morbidity and mortality costs).
Results: The COI was estimated to have increased by 66% from 96.1 billion yen in 1996 to 159.9 billion yen in 2011.
The number of deaths increased, but the proportion of those aged ≥65 years as a percentage of all deaths
remained mostly unchanged, with no increase in the average age at death. The mortality cost per person was
estimated to have increased (31.5 million yen in 1996 vs. 43.5 million yen in 2011). Assuming that the current trend
in health-related indicators continues, the COI is predicted to temporarily decrease in 2014, followed by almost no
change in 2020 (the estimated COI is 145.3–164.6 billion yen). The mortality cost per person is predicted to remain
almost unchanged (39.4–46.3 million yen in 2020).
Conclusions: The fact that the life expectancy of affected individuals is not being prolonged and that the mortality
in young individuals with a high human capital value is not decreasing may contribute to future sustainment of the
COI. We believe that the results of the present study are applicable to discussions of disease control priorities.
Keywords: Cost of illness (COI), Economic burden of disease, Cervical cancer, Health economics, Health policyBackground
Cervical cancer (ICD-10 code: C53) affected 9,794 Japanese
women in 2008 and resulted in 2,737 deaths in 2011,
making it the 9th most common type of cancer in terms
of morbidity and the 13th most common cancer in
terms of mortality in women in these years [1]. How-
ever, when limited to women aged <40 years, it is the
second most common cancer following breast cancer in
terms of morbidity and the third most common cancer fol-
lowing breast and stomach cancer in terms of mortality [1].
Because cervical cancer is associated with high morbid-
ity and mortality rates among relatively young women, its
economic burden is predicted to change as women’s* Correspondence: tommie@med.toho-u.ac.jp
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unless otherwise stated.participation in society increases. However, few studies
have estimated the economic burden of cervical cancer;
most reports have estimated only direct treatment costs
and performed cost-effectiveness analyses of specified
technologies [2-4]. No such long-term studies have been
conducted, and none have made future predictions. The
objectives of the present study were to assess the eco-
nomic burden of cervical cancer over time, make future
predictions based on these observations, and identify
the factors that drive the social burden of cervical
cancer.Methods
Analysis method
We used the cost of illness (COI) method to examine
the economic burden of cervical cancer. Government-
based statistical data and the COI method proposed byThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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COI includes both direct cost (DC) and indirect cost
(IC); IC includes morbidity cost (MbC) and mortality
cost (MtC). The COI is calculated using following
equation:
COI ¼ DCþMbCþMtC
DCs are medical costs that arise directly as a result of
disease, such as costs of treatment, hospitalization, test-
ing, and drugs. We calculated the annual medical costs
in the present study from the total medical expenses
using the Survey of National Medical Care Insurance
Services [13]. This survey only contains data for calculat-
ing DCs up to mid-level injuries and disease classifi-
cations such as uterine cancer (C53–55); it does not
contain lower-level injury and disease classifications,
such as cervical cancer of the uterus (C53). Therefore,
we calculated DCs by proportionally distributing medical
expenses based on the estimated number of patients
(ENP) for cervical cancer (C53), endometrial cancer
(C54), and other uterine cancers (C55) from the Patient
Survey of the Ministry of Health, Labour and Welfare
[14]. Thus, DC was calculated using the following
equation:
DC ¼ DC C53−55ð Þ  C C5C53ð Þ=ENP C53−55ð Þ
ICs are opportunity costs lost as a result of disease or
death. MbC and MtC were calculated using the follow-
ing equations:
MbC ¼ TOVy OLVd=2þ THD =LVd and
MtC ¼ NDy  LVl;
where TOVy is the total person-days of outpatient visits,
LVd is the 1-day labor value per person, THD is the total
person-days of hospitalization, NDy is the number of
deaths, and LVl is the lifetime labor value per person.
The TOVy and THD according to 5-year age groups
were calculated based on the above-mentioned Patient
Survey [14]. The labor values were calculated according
to 5-year age groups using the Basic Survey on Wage
Structure [15], Labor Force Survey [16], Estimates of
Monetary Valuation of Unpaid Work [17], and Evalua-
tions of Domestic Labor [18], each of which is associated
with a specific government office. The LVl was calcu-
lated by summing the income that could have been
earned in the future if death had not occurred. We cal-
culated the MbC by assuming a 1-day labor value loss
for 1 hospitalized day and a half-day labor value loss for
one outpatient visit. We used the number of deaths by
cervical cancer according to 5-year age groups from the
Vital Statistics of the Ministry of Health, Labour and
Welfare [19].LVd and THD were calculated as follows:
LVd ¼ Iy þ ULVyð Þ=365 and
THD ¼ HPy  ALOS;
where Iy is the annual income per person [15], ULVy is
the annual monetary valuation of unpaid work per per-
son [17,18], HPy is the annual number of hospitalized
patients [14], and ALOS is the average length of stay
[14]. The future labor value was adjusted to a present
value using a 3% discount rate because 3% is widely used
as discount rate in developed countries such as Japan
and the United States, where application of the COI
method is popular.
COI estimates over time
To examine changes over time, we first estimated the
COIs for 1996, 1999, 2002, 2005, 2008, and 2011 using
available data. The effect of introducing specific thera-
peutic techniques was not examined in this study.
Next, to make future predictions, we estimated the
COIs for 2014, 2017, and 2020 using the two methods
described below.
The first method involved fixing health-related indica-
tors (mortality rate, average number of outpatient visits,
average number of hospitalizations, average length of
stay, and medical fees per examination) at the 2011 values
and making estimates assuming changes in Japan’s popu-
lation and age composition (hereafter referred to as fixed-
model estimation). The data regarding medical fees per
examination were obtained from the Patient Survey [14].
Using 2011 as the standard year, we first calculated the
mortality rate, average number of outpatient visits, average
number of hospitalizations, and average length of stay
according to 5-year age groups in 2011. These data were
multiplied by the estimated populations for 2014, 2017,
and 2020 according to 5-year age groups to obtain the
predicted mortality rate, average number of outpatient
visits, average number of hospitalizations, and average
length of stay for each year. Using data from 2011, the
estimated average length of stay, mean life expectancy,
and labor value were used to estimate MbC and MtC.
DCs were calculated by multiplying the rate of increase in
outpatients and inpatients from 2011 to 2014, 2017, and
2020 by the outpatient and inpatient costs for 2011.
The second method involved making estimates assum-
ing continued trends in health-related indicators as well
as changes in population and age compositions. After
calculating approximation curves (logarithmic and linear
approximations) for each item using data after 1996, we
obtained figures for 2014, 2017, and 2020. We then
calculated the annual rate of increase in medical fees per
examination (outpatient and inpatient) [14] from 1996
to 2011 and corrected this increase by multiplying it by
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When making future predictions using this method,
estimates varied depending on which approximation
with which they were calculated. Three patterns of esti-
mates were made: estimates made from logarithmic
approximations of all items (logarithm-model estimation),
estimates made from linear approximations of all items
(linear-model estimation), and estimates made from ap-
proximations of items with higher determination coeffi-
cients (mixed-model estimation). Logarithmic and linearTable 1 Elements used for calculation of predicted future cos
Model Item Elements used for calculatio
Fixed model Number of deaths Mortality rate
The population estimates
Direct cost The expenses of outpatient vi
Medical fees per examination
Total person-days of outpatien
Total person-days of hospitaliz
Morbidity cost Average number of outpatien
Average number of hospitaliza
Average length of stay
The population estimates
Labor-value




・Logarithm model Number of deaths Mortality rate
・Linear model The population estimates
・Mixed model Direct cost The expenses of outpatient vi
Medical fees per examination
Total person-days of outpatien
Total person-days of hospitaliz
Morbidity cost Average number of outpatien
Average number of hospitaliza
Average length of stay
The population estimates
Labor-value




Fixed: The value for 2011 was used. Varied: The values for 2014, 2017, and 2020 we
Source of medical fees per examination: Patient Survey [14].
Source of average length of stay: Patient Survey [14].estimates would produce different annual trends depend-
ing on the item; thus, single estimates are likely to produce
overestimated or underestimated values. We therefore
compared determination coefficients within the same age
group in both the logarithmic and linear approximation
curves and performed a mixed estimate using the curve
with the higher coefficient in each age group. Mixed-
model estimation was considered the most likely estimates
in this study. The elements used for calculation of the pre-
dicted future COI are shown in Table 1.t of illness
n Fixed or Varied
Fixed
Varied













Varied (Calculated using the trend line formula)
Varied




t visits Varied (Calculated using the trend line formula)
(minimum value: the previous value before 0)
tions Varied (Calculated using the trend line formula)
(minimum value: the previous value before 0)
Varied (Calculated using the trend line formula)







re calculated based on the trend line.
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life expectancy and the labor value. Additionally, the
Population Estimates [20] by the Ministry of Internal
Affairs and Communications were used for 1996,
2002, 2005, 2008, and 2011 population statistics,
while the Population Projections for Japan [21] by the
National Institute of Population and Social Security
Research were used to make estimates for 2014, 2017,
and 2020.
For estimates using approximation curves, some future
predicted values may be <0; however, these are unlikely
to reflect actual clinical conditions. Therefore, we defined
“minimum values” in the present study as described
below. For mortality and the numbers of outpatients and
inpatients per person, the minimum value was set as the
value from the year prior to that in which the estimate
was <0. When examined according to age groups, we
assumed that the value from the year prior to that when
the estimate was <0 would be maintained thereafter and
thus applied this value when estimates for 2014, 2017, and
2020 fell to <0. The minimum value for the average length
of stay was set at 7.8 days, which is the average in 28
countries (2010) reporting data on neoplasms; this was
based on the average length of stay by diagnostic categor-
ies in the OECD Health Data 2013 (statistics and indi-
cators). According to the 2011 Patient Survey [14], the
average length of stay for cervical cancer (17.8 days) did
not differ greatly from the overall mean hospitalization
period for malignant neoplasms (20.6 days); thus, we set
the mean value for neoplasms in this study as theTable 2 Time trend of cost of illness of cervical cancer
1996 19
Population (thousand person) 125,864 12
[% of 65 years or older] 15.1% 16
Number of cervical cancer deaths (person) 2,219 2,2
[% of 65 years or older] 51.7% 51
Average age of death (year) 64.1 63
Crude incidence rate (per 100 thousand, female) 12.1 10
Crude mortality rate (per 100 thousand, female) 3.49 3.5
Fatality rate (female) 0.29 0.3
Direct cost (billion yen) 15.8 26
Morbidity cost (billion yen) 10.4 10
Mortality cost (billion yen) 69.9 74
[% of 65 years or older] 16.6% 15
Mortality cost per person (million yen) 31.5 33
COI (billion yen) 96.1 11
Source of population: Ministry of Internal Affairs and Communications, Population E
Source of number of cervical cancer deaths: Vital Statistics.
Average age of death: Calculated according to the number of deaths, age (5-year a
Source of crude morbidity rate and crude mortality rate: Center for Cancer Control
Fatality rate: Calculated by dividing the crude mortality rate by the crude morbidity
NA: not available.minimum length of stay for cervical cancer and applied
this to age groups with hospitalization periods of <7.8 days
in the estimates for 2014, 2017, and 2020. This study used
only aggregated and published nationwide data that are
freely available online; no humans or animals were used.
In Japan, no institutional review board approval is re-
quired for this type of study [22].
Results
COI estimates for 1996, 1999, 2002, 2005, 2008, and 2011
The COI was estimated at 96.1 billion yen in 1996,
110.6 billion yen in 1999, 131.7 billion yen in 2002,
133.4 billion yen in 2005, 145.5 billion yen in 2008, and
159.9 billion yen in 2011, indicating an increasing trend.
Comparison of estimates from 1996 and 2011 revealed
that the COI had increased by 66%. The number of deaths
increased, but the proportion of those aged ≥65 years as a
percentage of all deaths remained unchanged, with no
increase in the average age at death. No change was
observed in the fatality rate. The MtC per person cal-
culated by dividing the MtC by the number of deaths
followed an increasing trend (Table 2). Additional de-
tails of results (TOVy, THD, and LVl) are provided in
Additional file 1.
COI estimates for 2014, 2017, and 2020
(fixed-model estimation)
The COI was estimated at 159.5 billion yen for 2014,
158.9 billion yen for 2017, and 156.8 billion yen for
2020, with almost no change. DC, MbC, and MtC were99 2002 2005 2008 2011
6,686 127,435 127,768 127,692 127,799
.7% 18.5% 20.2% 22.1% 23.1%
60 2,443 2,465 2,486 2,737
.1% 47.7% 48.2% 47.7% 49.6%
.6 62.9 63.6 63.4 64.0
.7 13.5 13.0 15.0 NA
3 3.79 3.82 3.85 4.23
3 0.28 0.29 0.26 NA
.0 20.1 25.3 33.6 31.0
.1 12.8 10.3 10.6 9.9
.5 98.8 97.8 101.3 119.0
.4% 15.8% 16.9% 15.2% 17.5%
.0 40.4 39.7 40.7 43.5
0.6 131.7 133.4 145.5 159.9
stimates.
ge grades), and cause of death in Vital Statistics.
and Information Services, National Cancer Center, Japan.
rate.
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dicted number of deaths showed an increasing trend
and is expected to increase by 7.9% from 2011 to
2020. The proportion of deaths in individuals aged ≥65 years
is expected to increase (49.6% in 2011, 56.8% in 2020),Table 3 Future prediction of cost of illness
Model Item
Estimated population (thousand person)
[% of 65 years or older]
Fixed model Number of cervical cancer deaths (person)
[% of 65 years or older]
Average age of death (year)
Direct cost (billion yen)
Morbidity cost (billion yen)
Mortality cost (billion yen)
[% of 65 years or older]
Mortality cost per person (million yen)
COI (billion yen)
Linear model Number of cervical cancer deaths (person)
[% of 65 years or older]
Average age of death (year)
Direct cost (billion yen)
Morbidity cost (billion yen)
Mortality cost (billion yen)
[% of 65 years or older]
Mortality cost per person (million yen)
COI (billion yen)
Logarithm model Number of cervical cancer deaths (person)
[% of 65 years or older]
Average age of death (year)
Direct cost (billion yen)
Morbidity cost (billion yen)
Mortality cost (billion yen)
[% of 65 years or older]
Mortality cost per person (million yen)
COI (billion yen)
Mixed model Number of cervical cancer deaths (person)
[% of 65 years or older]
Average age of death (year)
Direct cost (billion yen)
Morbidity cost (billion yen)
Mortality cost (billion yen)
[% of 65 years or older]
Mortality cost per person (million yen)
COI (billion yen)
Source of estimated population, 2011: Ministry of Internal Affairs and Communicatio
and Social Security Research, Population Statistics of Japan.as is the average age at death (64.0 years in 2011,
66.3 years in 2020). The MtC of those aged ≥65 years
as a percentage of the total is expected to be 20.8%
in 2020, showing a decreasing trend in the MtC per
person.2011 2014 2017 2020
127,799 126,949 125,739 124,223
23.1% 26.1% 28.0% 29.1%
2,737 2,816 2,900 2,953
49.6% 53.0% 55.5% 56.8%
64.0 64.8 65.6 66.3
31.0 31.1 31.0 30.8
9.9 9.9 9.8 9.7
119.0 118.5 118.1 116.3
17.5% 19.3% 20.5% 20.8%
43.5 42.1 40.7 39.4
159.9 159.5 158.9 156.8
2,737 2,611 2,598 2,553
49.6% 48.3% 47.4% 45.0%
64.0 63.1 62.8 62.3
31.0 23.1 20.8 22.2
9.9 6.7 5.5 5.0
119.0 116.1 117.7 118.1
17.5% 16.4% 15.5% 13.9%
43.5 44.5 45.3 46.3
159.9 145.9 144.0 145.3
2,737 2,714 2,772 2,812
49.6% 52.6% 54.0% 54.6%
64.0 64.4 64.8 65.3
31.0 36.9 40.5 43.1
9.9 9.6 8.9 8.1
119.0 113.3 114.0 113.4
17.5% 19.0% 19.4% 19.2%
43.5 41.7 41.1 40.3
159.9 159.8 163.4 164.6
2,737 2,604 2,584 2,549
49.6% 49.7% 49.3% 48.0%
64.0 63.5 63.3 63.2
31.0 27.7 26.6 28.4
9.9 7.8 6.8 6.4
119.0 113.3 113.5 113.0
17.5% 17.5% 17.0% 16.0%
43.5 43.5 43.9 44.3
159.9 148.8 146.9 147.8
ns, Population Estimates 2014, 2017, and 2020: National Institute of Population
Figure 1 Time trends of cost of illness by prediction models.
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(linear-, logarithm-, and mixed-model estimations)
According to the linear-model estimation, the COI
was predicted to temporarily decrease to 145.9 billion
yen in 2014, after which it is predicted to remain
mostly unchanged at 144.0 billion yen in 2017 and
145.3 billion yen in 2020. This implies a 9.1% decrease
from 2011 to 2020. According to the logarithm-model
estimation, the COI is estimated to remain mostly un-
changed at 159.8 billion yen in 2014, 163.4 billion yen in
2017, and 164.6 billion yen in 2020. The predicted number
of deaths is predicted to decrease in the linear-model esti-
mation and increase in the logarithm-model estimation
(Table 3).
The linear-model estimation showed that DC, MbC,
and MtC will decrease temporarily in 2014, after which
they will remain mostly unchanged until 2020. The
logarithm-model estimation predicts that DC will in-
crease, whereas MbC and MtC will decrease.
According to the mixed-model estimation, the COI
was estimated to temporarily decrease to 148.8 billion
yen in 2014, after which it will remain mostly unchanged
at 146.9 billion yen in 2017 and 147.8 billion yen in 2020.
The rate of decrease from 2011 to 2020 is estimated at
7.6%. The number of deaths and the MbC are estimated
to decrease over time from 2011, and DC, MtC, and the
COI will temporarily decrease in 2014, after which they
are estimated to remain mostly unchanged until 2020. Al-
though mixed-model estimation is predicted to be below
fixed-model estimation for all items, they are predicted to
exceed linear estimates. The proportion of deaths in those
aged ≥65 years is expected to decrease to 48.0% in 2020,
and the average age at death will decrease to 63.2 years.
Furthermore, the MtC per person is predicted to in-
crease to 44.3 million yen, and the proportion of those
aged ≥65 years as a percentage of MtC is estimated to de-
crease to 16.0%.
The COI over time from 1996 is shown in Figures 1
and 2. The results suggest that the COI of cervical can-
cer will temporarily decrease and then remain mostly
unchanged.
Discussion
The COI increased from 1996 to 2011. Based on our fu-
ture predictions, the COI is estimated to remain un-
changed according to fixed-model estimates. However,
assuming that current trends in health-related indicators
continue, linear-model estimates show that the COI will
temporarily decrease in 2014, followed by almost no
change. On the other hand, logarithmic-model estimates
suggest that the trends will remain mostly unchanged
from 2011. Mixed-model estimates, which are con-
sidered the most reliable, show that despite the de-
creased number of deaths, the COI will remain mostlyunchanged from 2014, with DC and MtC following the
same trend. The main model used in our analysis was the
mixed model. The fixed model was a reference. The linear
and logarithm models provide low-end and high-end esti-
mation, respectively, and they can be regarded as sensitiv-
ity analyses that show the robustness of the mixed model.
Factors that influenced the increase in the COI from
1996 to 2011 were greater DC and MtC. In contrast,
MbC remained mostly unchanged. The medical fees per
examination of patients with uterine cancer increased by
5.3% annually, which is believed to be linked to greater
DC due to the increasing trend in the estimated number
of patients. The increase in medical fees per examination
is likely influenced by recent advancements in medical
care. On the other hand, the mean length of hospitaliza-
tion has shown a consistent downward trend, which may
explain the lack of the increase in MbC, canceling out the
increase in medical fees and opportunity costs lost as a
result of hospitalization. The increase in MtC is important
considering the age at death of patients with cervical can-
cer and the impact of aging in Japan. The average age at
death has remained mostly unchanged due to a twin-peak
pattern of increasing numbers of deaths at younger ages
(30–64 years) and older ages (≥75 years) [19]. In general,
because the fatality rate in the older population is high,
aging is a factor that increases the number of deaths and
MtC. However, aging also decreases MtC because older
individuals have relatively lower human capital value.
Thus, the impact of aging on MtC is relatively small.
However, increased numbers of deaths of young people
contributes significantly to the increase in MtC. The an-
nual labor value per person is increasing due to the in-
crease in the labor force participation rate among young
women and increasing annual incomes, which reflect the
social advancement of women. The increase in the num-
ber of deaths and labor value per person among young
women is believed to be a significant factor affecting the
increase in MtC (Table 4). In a previous report [23] in
Figure 2 Cost of illness projection with cost elements.
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same method described herein, the COI of stomach can-
cer decreased by 13.9% from 1996 to 2008, which can be
attributed to decreased MbC and MtC. Although the
number of stomach cancer-related deaths remained un-
changed, the average age at death increased, which may
have led to a decrease in the MtC per person and an over-
all decrease in MtC. Additionally, the decreased number
of outpatients and inpatients and shortened hospitali-
zation may have reduced MbC. The present study shows a
COI trend opposite to that in the above-mentioned study.
COI trends differ according to patient attributes and dis-
ease features, even for the same solid cancer. Comparison
of each factor influencing the COI would allow for evalu-
ation of the characteristics of the economic burden ofTable 4 Time trend of number of cervical cancer deaths, labo
labor value




1996 16 44 68 105 209
2011 19 68 118 202 219




1996 67.9 54.8 60.8 69.5 71.6
2011 77.0 67.5 67.0 71.2 75.7




1996 1817 1578 1802 2010 2036
2011 2176 2050 2132 2321 2457




1996 3584 4064 4288 4051 4078
2011 3493 4339 4900 5087 5004
changing rate -2.5% 6.8% 14.3% 25.6% 22.7
Source of number of cervical cancer deaths: Vital Statistics [19].
Source of labor force participation rate: Labor Force Survey, Ministry of Internal Affa
Source of annual income per person: Basic Survey on Wage Structure, Ministry of H
Annual labor value per person: Calculated according to annual income per person, labeach disease, which would contribute to the design of
future health policies.
According to our future predictions (fixed-model esti-
mation), the number of deaths will increase, but the COI,
DC, MbC, and MtC are estimated to remain unchanged.
In particular, MtC is estimated to decrease to no more
than 2.3% irrespective of the fact that the number of
deaths will increase by 7.8% from 2011 to 2020. The in-
crease in the proportion of deaths in those aged ≥65 years
(49.6% in 2011, 56.8% in 2020), the increase in the average
age at death (64.0 in 2011, 66.3 in 2020), and the decrease
in the MtC per person as a result of the reduced human
capital value (43.5 million yen in 2011, 39.4 million yen in
2020) are estimated to be offset by the pressure of in-
creased MtC from the increased number of deaths.r force participation rate, annual income, and annual
49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85-
195 210 224 256 233 251 208 200
221 228 304 231 220 281 270 356
13.3% 8.6% 35.7% -9.8% -5.6% 12.0% 29.8% 78.0%
66.9 58.1 39.0 27.0 10.1 0 0 0
72.6 64.0 45.7 27.6 8.6 0 0 0
8.5% 10.2% 17.2% 2.2% -14.9% 0.0% 0.0% 0.0%
1887 1555 969 664 248 0 0 0
2323 1942 1173 678 230 0 0 0
% 23.1% 24.9% 21.1% 2.1% -7.3% 0.0% 0.0% 0.0%
3745 3414 2837 2297 1684 1181 742 304
4681 4305 3223 2608 2301 1837 1513 800
% 25.0% 26.1% 13.6% 13.5% 36.6% 55.5% 103.9% 163.2%
irs and Communications [16].
ealth, Labour and Welfare [15].
or force participation rate, and estimates of monetary valuation of unpaid work.
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estimated to temporarily decrease in 2014, followed by
almost no change thereafter. The same trend is expected
for the number of deaths, DC, MbC, and MtC. The pro-
portion of deaths in those aged ≥65 years will decrease
(49.6% in 2011, 48.0% in 2020), as will the average age at
death (64.0 in 2011, 63.2 in 2020), and the MtC per per-
son will increase (43.5 million yen in 2011, 44.3 million
yen in 2020). The previously mentioned COI estimates
of stomach cancer [22] predict decreases in the number
of deaths, DC, MbC, MtC, and overall COI. In particu-
lar, a 25.1% decrease in the number of deaths and a
55.6% decrease in MtC from 2008 to 2020 are likely
factors influencing these estimates. The increase in the
average age at death and the sharp decline in the num-
ber of deaths among young people with a high human
capital value are predicted to be linked to decreased
MtC. Compared with stomach cancer, no increase in the
average age at death can be observed for cervical cancer,
and the lack of the reduction in the number of deaths
among young women with high human capital value is a
likely factor preventing future reductions in the COI.
COI may rather increase in the future because of the
promotion of women’s participation in society and the
increase in the human capital value of young people.
This finding suggests that interventions for younger
women can be an important political challenge. Several
studies on the economic burden of cervical cancer have
been conducted in other countries. For example, Ricciardi
et al. [24] estimated the annual DC of managing invasive
cancer in Italy as 28.3 million Euro per year. In 2003,
Olivia et al. [25] estimated the IC of cervical cancer in
Spain using two alternative approaches (human capital
method and friction cost method). The annual IC was es-
timated as 43.4 million Euro by the human capital method
and 1.1 million Euro by the friction cost method. How-
ever, no such long-term studies have been conducted, and
none have made future predictions. Therefore, this is one
of the advantages of our study.
Routine prophylactic vaccination against cervical can-
cer is currently being introduced in Japan. Prophylactic
vaccination against cervical cancer is expected to further
reduce the number of patients with cervical cancer and
related deaths, which should contribute to reducing the
COI.
A limitation of the present study is the fact that the
COI method only analyzes macroestimates of costs with-
out taking into account the quality of medical care or
quality of life, and it does not involve verification of the
cost effectiveness of microlevel therapeutic techniques.
Moreover, to who and what these costs apply is unclear.
For example, several studies have reported the economic
effects of prophylactic vaccination against human papillo-
mavirus [3,26-28], and prophylactic vaccination may helpto reduce the healthcare costs associated with cervical
cancer. Our study does not take the effect of a specific
treatment technology into consideration; a further study
of COI that includes the possible effect of prophylactic
vaccination against cervical cancer treatment would be
needed. In addition, because the annual labor value is
fixed at the 2011 value, as women’s participation in society
continues to accelerate and their incomes increase, MbC
and MtC are likely to be underestimated using this
method. However, the COI method enables the support of
rational decision-making through the efficient use of lim-
ited medical resources by measuring the monetary value
of disease burden [6,7]. Furthermore, this method pro-
vides basic information on policy-making related to pre-
vention and management activities for injuries and
diseases that justify intervention plans [10]. Therefore, the
knowledge obtained from the present study is valid and
can be applied to future policy-making.
Conclusions
We made future predictions of the COI of cervical cancer
using government statistics. According to our mixed esti-
mates, which are considered highly valid, if the current
trends in health-related indicators continue, the COI will
temporarily decrease in 2014, followed by almost no
change until 2020. The lack of a prolonged life expectancy
in individuals with cervical cancer and the lack of a de-
crease in the number of deaths among young women with
a high human capital value are likely factors preventing
a future reduction in the COI. Interventions involving
young women have high political priority because the COI
has high possibility to increase in the future secondary to
the promotion of women’s participation in society.
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